Cargando…
SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor
Disclosure: J. Setiawan: None. N.R. Mawji: None. A.H. Tien: None. R.J. Andersen: Stock Owner; Self; ESSA Pharma. M.D. Sadar: Stock Owner; Self; ESSA Pharma. Background: Androgen receptor (AR) is a steroid hormone receptor and a major therapeutic target in prostate cancer. Antiandrogen therapies dire...
Autores principales: | Setiawan, Josie, Mawji, Nasrin R, Tien, Amy H, Andersen, Raymond J, Sadar, Marianne D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555213/ http://dx.doi.org/10.1210/jendso/bvad114.1760 |
Ejemplares similares
-
SAT023 The Role Of Cysteine Residues In The Binding Of Inhibitors Of The N-Terminal Domain Of The Androgen Receptor
por: Deneault, Lauren, et al.
Publicado: (2023) -
SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma
por: Jordan Montgomery, Emma, et al.
Publicado: (2023) -
SAT019 Ligand-independent Signaling And Migration Of Breast Cancer Cells Overexpressing Membrane Androgen Receptor, ZIP9
por: Thomas, Peter
Publicado: (2023) -
SUN-022 Absence of Neuronal Androgen Receptor (AR) Improves Glucose Homeostasis in Female Mice
por: Morford, Jamie, et al.
Publicado: (2019) -
SAT-022 Improving The Diagnosis, Treatment, And Prevention Of Diseases Through Accurate And Reliable Laboratory Measurements With CDC Clinical Standardization Programs
por: Sugahara, Otoe, et al.
Publicado: (2019)